Literature DB >> 27539558

Determination of the Degradation Chemistry of the Antitumor Agent Pemetrexed Disodium.

Patrick J Jansen1, William K Smith2, Steven W Baertschi3, Douglas E Dorman2, Craig A J Kemp2, Karen A McCune2.   

Abstract

Stress-testing (forced degradation) studies have been conducted on pemetrexed disodium heptahydrate (1) (LY231514·2Na·7H2O) drug substance in order to identify its likely degradation products and establish its degradation pathways. Solid samples of the drug substance were stressed under various conditions of heat, humidity, and light, and solutions of the drug substance were stressed under various conditions of heat, light, oxidation, and over a wide pH range (1-13). The stressed samples were analyzed using a gradient elution reversed-phase HPLC method. The 7 major degradation products detected in the stress-testing studies were isolated, and the structures were elucidated via spectroscopic characterization. The structures of the degradation products and their proposed mechanisms of formation indicate that 1 degrades via 2 main pathways: oxidation and hydrolysis. Of the 7 identified degradation products, 6 are proposed to result from oxidation and 1 from hydrolysis.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LC-MS; chemical stability; degradation products; oxidation; photodegradation; stability

Mesh:

Substances:

Year:  2016        PMID: 27539558     DOI: 10.1016/j.xphs.2016.06.029

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies.

Authors:  Eleonora W J van Ewijk-Beneken Kolmer; Marga J A Teulen; Rene J Boosman; Nikki de Rouw; Jacobus A Burgers; Rob Ter Heine
Journal:  Biomed Chromatogr       Date:  2021-11-22       Impact factor: 1.911

2.  Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed.

Authors:  Dong Han Won; Heejun Park; Eun-Sol Ha; Yong Min Kim; Hyung Don Hwang; Sun Woo Jang; Min-Soo Kim
Journal:  Pharmaceutics       Date:  2020-01-06       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.